Boston Scientific
BSX
$45.05
+4.82%
Boston Scientific is a global medical device manufacturer focused on less invasive technologies inserted into the human body through small openings, spanning interventional cardiology, cardiac rhythm management, electrophysiology, endoscopy, urology, neuromodulation, and peripheral interventions, with foreign sales accounting for roughly 36% of the total. The company is a scaled med-tech leader with a market capitalization near $141 billion and approximately 59,000 employees, competing directly with Abbott, Medtronic, and Edwards Lifesciences across most of its end markets. The current investor narrative has turned sharply negative: the stock has lost more than half its value over the past year, with headlines citing underwhelming clinical trial results and a broad large-cap sell-off, even as management places a $1.5 billion strategic bet on MiRus's novel TAVR technology to enter the high-growth aortic stenosis market. Bulls argue the sell-off is overdone given the diversified portfolio and long-term track record, while bears point to decelerating momentum and the market's skepticism that the TAVR investment can offset pressure in core franchises.…
BSX
Boston Scientific
$45.05
Related headlines
Investment Opinion: Should I buy BSX Today?
Based on the synthesis, the recommendation is Hold with a speculative bias. The core thesis is that BSX is deeply undervalued on forward earnings (12.5x PE) and has strong analyst support (average target $62.41, implying 45% upside), but near-term earnings visibility is poor and momentum is overwhelmingly negative. The analyst consensus rating of 1.58 (Buy) and the average target price of $62.41 anchor the view that the sell-off may be overdone, but the stock lacks a clear catalyst to reverse the trend.
Supporting evidence includes: 1) Forward PE of 12.53x is well below the market average and the stock's own historical multiple; 2) Revenue grew 11.6% YoY in Q1 2026, with gross margin expanding to 69.4% from 63.3%; 3) TTM free cash flow of $3.44B provides financial flexibility; 4) The implied upside to the average analyst target is 45.2%, and the PEG ratio of 0.88 suggests undervaluation relative to growth. However, trailing EPS of $0.02 and a 48.6x trailing PE highlight the earnings disconnect.
The biggest risks are: 1) Continued earnings deterioration could lead to further analyst downgrades; 2) The MiRus TAVR investment may not offset weakness in core franchises; 3) Competitive pressures from larger peers could erode market share. The rating would upgrade to Buy if forward PE remains below 15x and revenue growth accelerates above 12%, or downgrade to Sell if revenue growth turns negative or free cash flow declines below $3B. Relative to its history, the stock is undervalued, but the market is pricing in significant uncertainty.
Sign up to view all
BSX 12-Month Price Forecast
The risk/reward is skewed to the upside given the deep valuation and strong analyst support, but the lack of near-term catalysts and negative momentum warrant a neutral stance. The stock is a show-me story: if Q2 2026 earnings demonstrate earnings recovery and the MiRus TAVR progresses, the stock could re-rate sharply. Conversely, another earnings miss could trigger a retest of lows. I would upgrade to bullish if forward PE remains below 15x and revenue growth accelerates above 12%, and downgrade to bearish if free cash flow declines below $3B or revenue growth turns negative.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Boston Scientific's 12-month outlook, with a consensus price target around $62.41 and implied upside of +38.5% versus the current price.
Average Target
$62.41
0 analysts
Implied Upside
+38.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$44 - $94
Analyst target range
Drowning in data?
Find the real signal!
Bulls vs Bears: BSX Investment Factors
The bear case currently has stronger evidence due to the severe price collapse, earnings deterioration, and negative momentum. The stock has lost nearly 60% of its value in a year, with trailing EPS of just $0.02 and a 48.6x trailing PE, while the S&P 500 has gained 16.2%. However, the bull case is not without merit: forward PE of 12.5x and a PEG of 0.88 suggest deep value if earnings recover, and analysts see 45% upside to their average target. The single most important tension is whether the MiRus TAVR investment and pipeline can reignite growth, or if the company faces structural challenges that justify the sell-off. Resolution of this debate will determine if the stock is a value trap or a generational buying opportunity.
Bullish
- Deep Value on Forward Earnings: Forward PE of 12.53x is remarkably low for a large-cap med-tech with 69% gross margins and 14.4% net margin. The PEG ratio of 0.88 (below 1.0) suggests the stock is undervalued relative to expected earnings growth, especially after a 58.8% one-year decline.
- Strong Analyst Consensus and Upside: 29 analysts rate BSX a 'buy' with a mean recommendation of 1.58 (where 1=Strong Buy, 5=Sell). The average target price of $62.41 implies 45.2% upside from the current $42.98, while the high target of $94 suggests 118.7% potential.
- Solid Profitability and Cash Generation: Q1 2026 revenue grew 11.6% YoY to $5.20B, with net income of $1.34B (25.7% net margin) and TTM free cash flow of $3.44B. Gross margin expanded to 69.4% in Q1 2026 from 63.3% a year earlier, demonstrating pricing power and operating leverage.
- Low Beta Defensive Profile: Beta of 0.568 indicates the stock is significantly less volatile than the broader market. In a risk-off environment, this defensive characteristic could attract investors seeking stability, especially given the stock's already depressed valuation.
Bearish
- Catastrophic Price Collapse: The stock has plummeted 58.8% over the past year and 54.6% YTD, massively underperforming the S&P 500 (SPY +16.2% 1Y, +12.1% YTD). Relative strength is deeply negative across all timeframes, with a 1-year relative strength of -75.0%.
- Severe Earnings Deterioration: Trailing EPS is just $0.02, resulting in a trailing PE of 48.6x, which is extremely high for a mature med-tech company. Q4 2025 EPS dropped to $0.45 from $0.90 in Q1 2026, and net income fell to $668M from $1.34B, indicating earnings volatility.
- Underwhelming Clinical Trial Results: Recent news (March 30, 2026) highlighted disappointing trial results that triggered a sharp sell-off. This raises concerns about the company's R&D pipeline and its ability to drive future growth through innovation.
- High Valuation Multiples Despite Crash: Despite the price decline, PS ratio is 7.03x, EV/EBITDA is 29.7x, and P/B is 5.82x—all elevated for a company with single-digit growth. The market may still be pricing in unrealistic growth expectations.
BSX Technical Analysis
Beta
0.57
0.57x market volatility
Max Drawdown
-60.6%
Largest decline past year
52-Week Range
$42-$106
Price range past year
Annual Return
-56.1%
Cumulative gain past year
| Period | BSX Return | S&P 500 |
|---|---|---|
| 1m | -13.1% | -2.0% |
| 3m | -4.0% | +1.4% |
| 6m | -36.8% | +15.0% |
| 1y | -56.1% | +15.7% |
| ytd | -52.4% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BSX Fundamental Analysis
Quarterly Revenue
$5.2B
2026-03
Revenue YoY Growth
+11.6%
YoY Comparison
Gross Margin
69.4%
Latest Quarter
Free Cash Flow
$3.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BSX Overvalued?
PE
48.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 17x~88x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. The company's trailing EPS of $0.02 yields a trailing PE of 48.6x, indicating that current earnings are near zero and highly volatile. While Q1 2026 net income was $1.34B, Q4 2025 net income was only $668M, a 50% sequential decline, highlighting earnings instability. Debt-to-equity of 0.51 is manageable, but the current ratio of 1.62 suggests adequate liquidity. Free cash flow of $3.44B TTM is a strength, but if earnings continue to disappoint, cash flow could come under pressure. The $1.5B MiRus investment is a substantial bet that may not pay off if TAVR competition intensifies.
Market and competitive risks are elevated. The stock's beta of 0.568 indicates lower volatility than the market, but it has still suffered a 58.8% decline, suggesting company-specific issues. The medical device sector is highly competitive, with Abbott, Medtronic, and Edwards all vying for share. BSX's PS ratio of 7.03x and EV/EBITDA of 29.7x are premium multiples that could compress further if growth stalls. Recent news of underwhelming trial results has damaged investor confidence, and the broad large-cap sell-off has exacerbated the decline. Regulatory risks, including potential changes to healthcare reimbursement, could also impact future revenues.
In a worst-case scenario, if the MiRus TAVR investment fails to gain traction and core franchises continue to lose share, the stock could retest its 52-week low of $42.20, representing a 1.8% decline from the current $42.98. However, the analyst low target of $44.00 is slightly above the current price, suggesting limited downside according to analysts. A more severe scenario, such as a recession or major clinical setback, could push the stock below $40, implying a 7% loss. The maximum drawdown over the past year was -60.58%, so investors could face further losses if negative momentum persists. The key risk is that the market's skepticism becomes self-reinforcing, leading to a prolonged downturn.
FAQ
The key risks are: 1) Earnings risk – trailing EPS of $0.02 and a 48.6x trailing PE mean any earnings miss could trigger a sharp sell-off; 2) Competitive risk – BSX faces intense competition from Abbott, Medtronic, and Edwards, and recent underwhelming trial results have raised concerns about its pipeline; 3) Macro risk – with a beta of 0.568, the stock is less volatile than the market, but a broad sell-off or recession could still pressure the stock, especially given its 36% foreign sales exposure; 4) Execution risk – the $1.5B MiRus TAVR investment is a significant bet that may not pay off if the technology fails to gain traction. Ranked by severity, earnings risk is highest, followed by competitive and execution risks.
Our 12-month forecast has three scenarios: Bull (25% probability) with a target range of $62-$94, assuming successful TAVR integration and earnings recovery; Base (55% probability) with a target range of $50-$62, assuming gradual stabilization and meeting consensus estimates; Bear (20% probability) with a target range of $35-$44, assuming continued earnings misses and competitive pressures. The base case is most likely, with a target around the analyst average of $62.41, implying 45% upside. The key assumption is that forward EPS of $4.52 is achieved and the forward PE expands modestly to 13-15x. However, if earnings disappoint, the bear case could materialize, pushing the stock to the low $40s or below.
BSX appears undervalued on forward earnings but overvalued on trailing metrics. The forward PE of 12.53x is well below the S&P 500 average and the stock's own 5-year average of ~25x, while the PEG ratio of 0.88 suggests undervaluation relative to growth. However, the trailing PE of 48.6x and PS ratio of 7.03x are elevated, reflecting depressed trailing earnings. The market is pricing in a significant earnings recovery, as evidenced by the large gap between trailing and forward PE. If the company meets forward EPS estimates of $4.52, the stock is cheap; if it misses, the valuation could compress further. Relative to peers like Medtronic (forward PE ~15x) and Abbott (forward PE ~20x), BSX trades at a discount, but the discount may be justified by its weaker earnings trajectory.
From a risk/reward perspective, BSX offers a compelling opportunity for patient investors. The stock trades at a forward PE of 12.53x, a steep discount to its historical average, and analysts see 45% upside to their average target of $62.41. However, the trailing PE of 48.6x and EPS of $0.02 highlight that current earnings are weak, and the stock has fallen 58.8% over the past year. The biggest downside risk is a retest of the 52-week low of $42.20, which is only 1.8% below the current price, suggesting limited further downside. For long-term investors comfortable with volatility, BSX could be a good buy, but near-term traders may want to wait for a catalyst.
BSX is more suitable for long-term investment (minimum 2-3 years) given its depressed earnings, ongoing turnaround efforts, and the need for the MiRus TAVR investment to mature. The stock does not pay a dividend, so returns depend entirely on capital appreciation. Its beta of 0.568 suggests lower volatility, but the 58.8% one-year decline shows it is not immune to sharp drawdowns. Short-term trading is risky due to the lack of near-term catalysts and negative momentum. A suggested minimum holding period is 2 years to allow for earnings recovery and pipeline developments. Investors should monitor quarterly earnings and clinical trial updates closely.
